CD44 and acute myeloid leukemia: Furthermore, anti-CD44 is available as a clinical-grade humanized monoclonal antibody (RG7356), has been trialed as a therapy for CD44-expressing solid tumors [46] and been found to be safe and well tolerated as a monotherapy in a phase 1 trial for AML [47].